Literature DB >> 8467871

The sigma receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia.

N G Rückert1, W J Schmidt.   

Abstract

The behavioral effects of the selective sigma ligand 1,3-di(2-tolyl)guanidine (DTG) were studied in rats. In the radial 8-arm maze, DTG (2, 4 and 8 mg/kg i.p.) reduced the number of arm entries in the spontaneous alternation task. In animals receiving 4 mg/kg DTG, the percentage of 135 degrees angles between consecutive arm entries decreased. In the open field, equipped with a holeboard, DTG (8 mg/kg) reduced the number of line crossings, rearings and head dips. Sniffing, measured in an experimental chamber, was also reduced. DTG prolonged the time that the animals were inactive. In combination with DL-amphetamine (4 mg/kg) or dizocilpine (0.16 mg/kg), DTG (8 mg/kg) decreased--but did not antagonize--the induced enhancement of locomotion and sniffing. These results demonstrate motor depressant effects of DTG on locomotion, rearing and sniffing. Since antagonists of sigma binding sites are known to produce opposite effects, we conclude that DTG--in behavioral terms--acts like an antagonist at sigma binding sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467871     DOI: 10.1016/0014-2999(93)90059-q

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Werner J. Schmidt (1950-2007). Pushing the boundary of neuroscience: a true academician and a complete gentleman.

Authors:  Trevor Archer; Richard J Beninger
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

2.  6-Hydroxydopamine lesion of locus coeruleus and the antiparkinsonian potential of NMDA-receptor antagonists in rats.

Authors:  N Rückert; M Bubser; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Low dose of 1,3-di(2-tolyl)guanidine (DTG) attenuates MK-801-induced spatial working memory impairment in mice.

Authors:  T Maurice; M Hiramatsu; J Itoh; T Kameyama; T Hasegawa; T Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

4.  Behavioral Effects of a Potential Novel TAAR1 Antagonist.

Authors:  Vincent M Lam; Catharine A Mielnik; Corey Baimel; Pieter Beerepoot; Stefano Espinoza; Ilya Sukhanov; Wendy Horsfall; Raul R Gainetdinov; Stephanie L Borgland; Amy J Ramsey; Ali Salahpour
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

5.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.